Directorio

People in this study may get up to 8 treatment cycles. Each cycle lasts 21 days. Usually, there are 3 to 4 cycles before surgery and 2 to 4 cycles after surgery, depending on how the cancer responds and what the doctor decides. The whole treatment takes about 8 months, and doctors will check on patients for up to 15 more months. This means the study lasts about 24 months in total. Doctors will place patients into one of three groups (A, B, or C). This is not random. All groups will get a medicine called TORL 123. Group A: TORL 123 plus paclitaxel Group B: TORL 123 plus carboplatin Group C: TORL 123 plus both paclitaxel and carboplatin Medicine is given through an IV on Day 1 of each cycle. There will also be extra visits and blood tests during the cycle.

This study includes one virtual information session, some online questionnaires, five in person visits, and a twelve week exercise program that is supervised from home. All in person visits will happen at the Duke Center for Living in Durham. The exercise program includes both aerobic exercise and strength training. Each week there will be Zoom exercise classes led by a study staff member, along with workouts you complete on your own using materials the study provides.

We are doing this study to compare 2 different surgical options for the prevention of ovarian cancer. We want to know which option is likely to produce the best outcomes for women who have genetic mutations that put them at high risk for developing ovarian cancer.

No Treatment. Patients who agree to participate in this study will be enrolled in the TxAccess software platform Participants will fill out questionnaires and have additional blood tests.

Everyone in the study will get a medicine called Quisinostat. The study will last about 3 years and has three parts: - Screening Period – doctors check if you can join - Treatment Period – you take the medicine - Follow-Up Period – doctors check how you\'re doing after treatment

We are doing this study to evaluate the safety and effectiveness of a drug called isatuximab when it is used in combination with lenalidomide and dexamethasone at lower doses. We want to know if this low dose combination can help patients with multiple myeloma achieve a better response while causing fewer or less severe side effects.

We are doing this study to learn more about variants in people's genes that cause cells in the back of the eye to function incorrectly and lead to a process called "retinal degeneration."